USFDA accepts application for Merck KEYTRUDA plus Chemotherapy as first line treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Ruchika Sharma14 April 2023 5:30 AM GMTKEYTRUDA is an anti-programmed death receptor-1 therapy that works by increasing the ability of the body's immune system to help detect and fight...
Merck Keytruda gets full USFDA approval for advanced MSI-H or dMMR solid tumors Ruchika Sharma1 April 2023 6:45 AM GMTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
